Background
Methods
Patients and serum samples
Basic data and study endpoint
Renal histopathology
Measurement of the 25-hydroxyvitamin D
Statistical analyses
Results
Basic clinical information of the participants
Total (n = 105) | |
---|---|
Age (year) | 34.73 ± 12.19 |
Male (n/%) | 57(54.3 %) |
Smoker (n/%) | 32(30.5 %) |
Body mass index (kg/m2) | 23.2 ± 3.18 |
Systolic blood pressure (mmHg) | 131.21 ± 23.43 |
Diastolic blood pressure (mmHg) | 81.57 ± 16.84 |
Microscopic hematuria (n/%) | 67 (63.8 %) |
Proteinuria(g/24 h) | 2.04 ± 1.09 |
eGFR (mL/min/1.73 m2) | 75.45 ± 39.18 |
Serum albumin (mg/dL) | 33.88 ± 7.91 |
Serum total cholesterol (mg/dL) | 5.76 ± 2.09 |
Serum IgA (mg/dL) | 2.97 ± 1.92 |
Uric acid (mg/dL) | 404.81 ± 123.59 |
Medical treatment (n/%) | |
RAS blockers | 83 (79 %) |
Immunosuppressant | 38 (36.2 %) |
Variables | Serum 25-hydroxyvitamin (ng/mL) | P-value | |
---|---|---|---|
≥15 ng/mL | <15 ng/mL | ||
Age (years) | 36.19 ± 10.86 | 32.87 ± 13.62 | 0.18 |
Body mass index (kg/m2) | 23.05 ± 2.86 | 23.39 ± 3.57 | 0.59 |
Systolic blood pressure (mmHg) | 123.95 ± 17.26 | 140.52 ± 26.96 | 0.001 |
Diastolic blood pressure (mmHg) | 76.66 ± 14.47 | 87.87 ± 17.70 | 0.001 |
Proteinuria(g/24 h) | 1.23 ± 1.27 | 3.07 ± 2.06 | <0.001 |
eGFR (mL/min/1.73 m2) | 83.42 ± 32.64 | 65.24 ± 44.56 | 0.023 |
CKD stage 1(n/%) | 18 (45 %) | 22 (55 %) | 0.069 |
CKD stage 2(n/%) | 16 (57.1 %) | 12 (42.9 %) | |
CKD stage 3(n/%) | 8 (38.1 %) | 13 (61.9 %) | |
CKD stage 4(n/%) | 1 (16.7 %) | 5 (83.3 %) | |
CKD stage 5(n/%) | 1 (10 %) | 9 (90 %) | |
Serum albumin (mg/dL) | 38.08 ± 5.02 | 28.50 ± 7.72 | <0.001 |
Serum total cholesterol (mg/dL) | 5.14 ± 1.21 | 6.57 ± 2.64 | <0.001 |
Serum IgA (mg/dL) | 3.15 ± 2.24 | 2.73 ± 1.38 | 0.27 |
Uric acid (mg/dL) | 374.31 ± 112.68 | 443.93 ± 127.11 | 0.004 |
The correlation between clinical parameters and 25(OH)D
proteinuria | 25(OH)D | SBP | ALB | UA | |
---|---|---|---|---|---|
eGFR | −0.377** | 0.196* | −0.656** | 0.155 | −0.513** |
proteinuria | 1 | −0.553** | 0.464** | −0.564** | 0.219* |
25(OH)D | 1 | −0.316** | 0.665** | −0.140 | |
SBP | 1 | −0.272** | 0.302*** | ||
ALB | 1 | −0.065 | |||
UA | 1 |
Relationship between histologic features and the plasma 25(OH)D
Oxford score | 25(OH)D level (ng/ml) |
P
|
---|---|---|
M0 | 14.55 ± 8.70 | 0.142 |
M1 | 12.10 ± 7.72 | |
E0 | 13.76 ± 8.50 | 0.443 |
E1 | 11.44 ± 4.19 | |
S0 | 11.79 ± 8.22 | 0.198 |
S1 | 15.17 ± 8.33 | |
T0 | 15.41 ± 8.89 | 0.008 |
T1 | 11.07 ± 6.80 | |
T2 | 8.84 ± 4.75 |
The impact of circulating 25(OH)D on clinical outcome
HR (95 % CI) | P value | |
---|---|---|
Vitamin D deficiency | 5.99 (1.59–22.54) | 0.008 |
Male | 1.87 (0.59–5.94) | 0.287 |
eGFR | 0.99 (0.97–1.01) | 0.145 |
SBP | 1.03 (1.00–1.05) | 0.036 |
ALB | 1.05 (0.99–1.12) | 0.103 |
T0(reference) | 1 | |
T1-2 | 2.76 (0.68–11.24) | 0.156 |
Proteinuria | 1.14 (0.82–1.57) | 0.432 |